ALC Stock Analysis: Alcon | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 26.677m CHF | 12M Return: -23.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 76.0M
EPS Trend: 87.0%
Qual. Beats: 1
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alcon Inc. (ALC) is a Switzerland-headquartered global eye care company that operates through two segments: Surgical and Vision Care. The Surgical segment provides equipment, instrumentation, diagnostics, intraocular lenses (IOLs), and other implantables, along with consumables used in cataract, vitreoretinal, and refractive (LASIK) procedures. The Vision Care segment offers daily disposable, reusable, and color-enhancing contact lenses, plus ocular health products spanning dry eye, allergies, glaucoma, contact lens care, ocular vitamins, and redness relievers.
The company is one of the largest pure-play ophthalmic medical device and consumer eye care businesses in the world, competing primarily in the global eye care industry alongside Bausch + Lomb and Johnson & Johnson Vision. Demand for its products is structurally supported by aging demographics, rising rates of cataracts, presbyopia, and refractive errors, and increasing access to vision correction in emerging markets. Founded in 1945 and headquartered in Geneva, Alcon was formerly known as Alcon Universal S.A. before adopting its current name in December 2001.
- Premium IOL adoption lifts Surgical segment growth
- Vision Care pricing squeezed by Bausch + Lomb and J&J
- Strong Swiss franc creates persistent FX translation headwinds
| Net Income: 816.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: 34.22% < 20% (prev 38.50%; Δ -4.27% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.27b > Net Income 816.6m |
| Net Debt (4.12b) to EBITDA (2.25b): 1.83 < 3 |
| Current Ratio: 2.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (490.2m) vs 12m ago -1.57% < -2% |
| Gross Margin: 55.36% > 18% (prev 55.55%; Δ -0.19% > 0.5%) |
| Asset Turnover: 33.79% > 50% (prev 32.01%; Δ 1.78% > 0%) |
| Interest Coverage Ratio: 4.59 > 6 (EBIT TTM 947.4m / Interest Expense TTM 206.3m) |
| DSRI: 1.02 (Receivables 2.02b/1.86b, Revenue 10.6b/9.93b) |
| GMI: 1.00 (GM 55.55% / 55.36%) |
| AQI: 0.97 (AQ_t 0.63 / AQ_t-1 0.65) |
| SGI: 1.07 (Revenue 10.6b / 9.93b) |
| TATA: -0.05 (NI 816.6m - CFO 2.27b) / TA 31.7b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at CHF 55.68 with a total of 1,702,130 shares traded. Over the past week, the price has changed by -1.90%, over one month by +2.09%, over three months by -6.50% and over the past year by -23.06%.
Current recommended Stop Loss: 52.90 (which is 5% or 2.3 ATR below the current price).
Alcon has no consensus analysts rating.
Market Cap USD = 32.8b (26.7b CHF * 1.2277 CHF.USD)
P/E Trailing = 40.5185
P/E Forward = 19.5695
P/S = 2.5087
P/B = 1.4935
P/EG = 1.5174
Revenue TTM = 10.6b USD
EBIT TTM = 947.4m USD
EBITDA TTM = 2.25b USD
Long Term Debt = 4.16b USD (from longTermDebt, last quarter)
Short Term Debt = 648.0m USD (from shortTermDebt, last quarter)
Debt = 5.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 528.0m
Net Debt = 4.12b USD (calculated: Debt 5.78b - CCE 1.66b)
Enterprise Value = 36.9b USD (32.8b + Debt 5.78b - CCE 1.66b)
Interest Coverage Ratio = 4.59 (Ebit TTM 947.4m / Interest Expense TTM 206.3m)
EV/FCF = 21.61x (Enterprise Value 36.9b / FCF TTM 1.71b)
FCF Yield = 4.63% (FCF TTM 1.71b / Enterprise Value 36.9b)
FCF Margin = 16.10% (FCF TTM 1.71b / Revenue TTM 10.6b)
Net Margin = 7.71% (Net Income TTM 816.6m / Revenue TTM 10.6b)
Gross Margin = 55.36% ((Revenue TTM 10.6b - Cost of Revenue TTM 4.73b) / Revenue TTM)
Gross Margin QoQ = 56.36% (prev 55.78%)
Tobins Q-Ratio = 1.16 (Enterprise Value 36.9b / Total Assets 31.7b)
Interest Expense / Debt = 3.57% (Interest Expense 206.3m / Debt 5.78b)
Taxrate = 16.92% (166.3m / 982.9m)
NOPAT = 787.1m (EBIT 947.4m * (1 - 16.92%))
Current Ratio = 2.20 (Total Current Assets 6.64b / Total Current Liabilities 3.01b)
Debt / Equity = 0.26 (Debt 5.78b / totalStockholderEquity, last quarter 22.2b)
Debt / EBITDA = 1.83 (Net Debt 4.12b / EBITDA 2.25b)
Debt / FCF = 2.41 (Net Debt 4.12b / FCF TTM 1.71b)
Total Stockholder Equity = 22.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.60% (Net Income 816.6m / Total Assets 31.7b)
RoE = 3.70% (Net Income TTM 816.6m / Total Stockholder Equity 22.1b)
RoCE = 3.61% (EBIT 947.4m / Capital Employed (Equity 22.1b + L.T.Debt 4.16b))
RoIC = 2.73% (NOPAT 787.1m / Invested Capital 28.8b)
WACC = 6.17% (E(32.8b)/V(38.5b) * Re(6.74%) + D(5.78b)/V(38.5b) * Rd(3.57%) * (1-Tc(0.17)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.59 | Cagr: -0.56%
[DCF] Terminal Value 76.08% ; FCFF base≈1.67b ; Y1≈1.75b ; Y5≈2.01b
[DCF] Fair Price = 55.14 (EV 31.0b - Net Debt 4.12b = Equity 26.9b / Shares 487.7m; r=8.35% [WACC [floored]]; 5y FCF grow 4.99% → 2.50% )
EPS Correlation: 86.99 | EPS CAGR: 9.61% | SUE: 0.88 | # QB: 1
Revenue Correlation: 99.06 | Revenue CAGR: 5.17% | SUE: -0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.76 | Chg30d=-0.04% | Revisions=-50% | Analysts=16
EPS next Quarter (2026-09-30): EPS=0.57 | Chg30d=+2.78% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=3.47 | Chg30d=-0.01% | Revisions=+40% | GrowthEPS=+12.9% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=4.38 | Chg30d=+0.82% | Revisions=+40% | GrowthEPS=+26.2% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +6% (up=7, down=6)